Clinical trials: Demyelinating Disorder
Multiple Sclerosis
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
To evaluate the efficacy and safety of AIN457 versus placebo in patients with relapsing multiple sclerosis.
- Trial name
- NCT01874340
- Testing
- AIN457
- Where
- 13 sites in Belgium, Czechia and 8 more
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Adrenoleukodystrophy, Metachromatic Leukodystrophy
HSCT for High Risk Inherited Inborn Errors
Hematopoietic stem cell transplantation has proven effective therapy for individuals with adrenoleukodystrophy (ALD), metachromatic leukodystrophy (MLD) or globoid cell leukodystrophy (GLD, or Krabbe disease).
- Conditions
- Adrenoleukodystrophy, Metachromatic Leukodystrophy, Globoid Cell Leukodystrophy, Tay Sachs Disease
- Trial name
- NCT00383448
- Testing
- Clofarabine, Total body Irradiation, Melphalan
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Relapsing-remitting Multiple Sclerosis
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
This study assessed the efficacy, safety, and tolerability of 2 doses of oral fingolimod (1.25 mg/day and 0.5 mg/day) compared to placebo in patients with relapsing-remitting multiple sclerosis (RRMS)
- Trial name
- FREEDOMS (NCT00289978)
- Testing
- Fingolimod 1.25 mg, Fingolimod 0.5 mg
- Where
- 115 sites in Australia, Belgium and 17 more
- Volunteers
- 1,272 people
- Sponsor
- Novartis
Multiple Sclerosis
Protective Stepping in People With MS
Falls are common in Veterans with multiple sclerosis (MS), and current rehabilitation approaches to reduce falls are inadequate.
- Trial name
- PRO-STEP (NCT03551665)
- Testing
- Protective step training
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis
Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY
The primary purpose of this single center, randomized, open label study in relapsing Multiple Sclerosis (MS) patients on PLEGRIDY (peginterferon beta-1a) is to assess the effect of Preparation H (phenylephrine) Maximum Strength…
- Trial name
- NCT02665221
- Testing
- No Treatment Arm, Topical Preparation H arm
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Progressive Multiple Sclerosis, Fatigue
A Study of Oxidative Pathways in MS Fatigue
This is a 4-week randomized, placebo-controlled, parallel group, double-blind, single center trial on effect of N-acetyl cysteine versus placebo on fatigue in patients with progressive MS defined by McDonald criteria.
- Trial name
- NCT02804594
- Testing
- N-acetyl cysteine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, San Francisco
Multiple Sclerosis
MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)
This is a prospective, multicenter, open label, uncontrolled, non-interventional, single arm study to measure treatment satisfaction of relapsing remitting MS (RRMS) participants on Rebif after discontinuing initial first-line…
- Trial name
- MESTRE-MS (NCT02949908)
- Testing
- Rebif
- Where
- Germany
- Volunteers
- 2 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
Long-term Follow-up of Fingolimod Phase II Study Patients
This study collected follow-up data on approximately 90% of participants who were randomized and received one dose of study drug in FTY720D2201 (D2201). No study drug was given or required.
- Trial name
- ACROSS (NCT02307838)
- Testing
- Assessments arm
- Where
- 26 sites in Canada, Denmark and 8 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Combined Effect of Transcranial Direct Current Stimulation (tDCS) and Physical Activity on Gait and Functional Mobility in Participants With Multiple Sclerosis
This study is aimed to test the efficacy of transcranial direct current stimulation (tDCS) combined with a physical activity (PA) program, in 80 individuals affected by Multiple Sclerosis (MS).
- Trial name
- NCT03658668
- Testing
- active tDCS, Physical Activity (PA)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- NYU Langone Health
Multiple Sclerosis
Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS
The primary objective of this study is to determine if monthly pulse doses of a three-day course ACTH (H.P. Acthar®) is more effective at recovering myelin at 12 months, as measured by myelin water fraction (MWF), in new multiple…
- Trial name
- NCT02446886
- Testing
- Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Multiple Sclerosis, Relapsing-Remitting
A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)
The purpose of this study was to evaluate the improvement in spontaneous recovery from clinical deficits at the time of an acute relapse in RR-MS participants already receiving interferon (IFN) beta 1a with D-aspartate (versus…
- Trial name
- INCREASE (NCT03387046)
- Testing
- D-aspartate, IFN beta-1a, Methylprednisolone
- Where
- 17 sites in Italy
- Volunteers
- 7 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing-Remitting
Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis
The trial will study 2 doses of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) for the number of relapses that occur in a 1 year treatment period.
- Trial name
- PRIVIG (NCT00220779)
- Testing
- Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
- Where
- 37 sites in United States, Austria and 10 more
- Volunteers
- 128 people
- Sponsor
- Grifols Therapeutics LLC
Neuromyelitis Optica Spectrum Disorder
A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
This multicenter, single-arm, open-label study will evaluate the long-term safety and efficacy of satralizumab in participants with neuromyelitis optica spectrum disorder (NMOSD) who completed open-label extension (OLE) period of…
- Trial name
- NCT04660539
- Testing
- satralizumab, azathioprine (AZA), mycophenolate mofetil (MMF)
- Where
- 53 sites in United States, Bulgaria and 16 more
- Volunteers
- 119 people
- Sponsor
- Hoffmann-La Roche
Secondary Progressive Multiple Sclerosis
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Evaluate the safety and efficacy of Siponimod (BAF312) versus placebo in a variable treatment duration in patients with secondary progressive multiple sclerosis (Core Part) followed by extended treatment with open-label BAF312 to…
- Trial name
- NCT01665144
- Testing
- BAF312
- Where
- 290 sites in United States, Argentina and 29 more
- Volunteers
- 1,651 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis
The purpose of this study was to assess the efficacy of Sativex in relieving symptoms of spasticity in multiple sclerosis
- Trial name
- NCT01599234
- Testing
- Sativex
- Where
- United Kingdom
- Volunteers
- 337 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis, Immune System Diseases
Mechanism of Action of Ocrelizumab in Multiple Sclerosis
Ocrelizumab is FDA approved for therapy of multiple sclerosis (MS). It depletes B cells and stops MS inflammation.
- Trial name
- NCT03344094
- Testing
- ocrelizumab
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Multiple Sclerosis, Relapsing-remitting
Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health
This is a pilot study of oral vitamin D supplementation to determine if patients with Multiple Sclerosis (MS) and healthy individuals attain a similar increase in serum 25-hydroxyvitamin D levels.
- Trial name
- NCT01667796
- Testing
- Vitamin D3
- Where
- 2 sites in United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Multiple Sclerosis, Internuclear Ophthalmoplegia
Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis
Primary fatigue represents a major cause of disability in patients with multiple sclerosis (MS), being reported in about 90% of cases.
- Conditions
- Multiple Sclerosis, Internuclear Ophthalmoplegia, Fatigue
- Trial name
- NCT02391961
- Testing
- Dalfampridine
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis
Assessing Tolerability of Avonex Intramuscular Injections
The purpose of this study is to evaluate patients' views when injecting Avonex intramuscularly.
- Trial name
- NCT01641120
- Testing
- Avonex
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Trinity Health Of New England
Multiple Sclerosis
Locomotor Training in Persons With Multiple Sclerosis
Locomotor training is a new exercise modality that emphasizes task specificity to promote learning and neural plasticity. It has been reported to improve walking in patients with stroke, spinal cord injury and cerebral palsy.
- Trial name
- NCT00607126
- Testing
- Lokomat, resistive training
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of California, Los Angeles